InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Saturday, 04/29/2017 10:36:48 AM

Saturday, April 29, 2017 10:36:48 AM

Post# of 807
Another Win for CAR-T Therapy
Study shows benefit in children with CNS-relapsed ALL

In a secondary analysis of the phase I/IIa CHP 959 study, looking only at children with CNS involvement, 71% remain in complete remission a median of 11 months after the therapy, reported Mala Talekar, MD, from Children's Hospital of Philadelphia.
Presenting the findings at the annual meeting of the American Society of Pediatric Hematology/Oncology here, Talekar said the "remarkable milestone" underscores the potential for CTL019


HTTPS://www.medpagetoday.com/meetingcoverage/additionalmeetings/64895